Overview

A Single Dose Study Of PF-05161704 In Healthy Volunteers

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single oral doses of PF-05161704 in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer